Contribute Try STAT+ Today

For the last seven years, Michael Snyder has meticulously tracked his microbiome, monitoring how much glucose and how many proteins from immune cells were in his blood and which bacteria were living in his nose and gut — as he became diabetic, got his diabetes under control, and then lost that control.

And now, that research on his own gut — and similar tracking for more than 100 other participants in a major study he led as part of the NIH-backed Human Microbiome Project — is being made public this week in Nature and Nature Medicine, along with two other major microbiome analyses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.